Denise Lynn Sherk, FNP

Denise Sherk practices at Pet CT Pob - Positron Emission Tomography, Computed Tomography Professional Office Building - HOPD in Murrieta, California.

Denise Sherk's NPI, 1356681985, was assigned on February 19, 2013. Denise Sherk holds California license 21415.

Denise Sherk's primary practice is Pet CT Pob - Positron Emission Tomography, Computed Tomography Professional Office Building - HOPD, at 28078 Baxter Road, Murrieta, CA 92563.

Denise Sherk's primary practice is Pet CT Pob - Positron Emission Tomography, Computed Tomography Professional Office Building - HOPD in Murrieta, California. The medical group on file is United Medical Doctors. Dmand AI also links Denise Sherk to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Denise Sherk practices, 2 sites in all. Vendor and product names are available with a free account.

Family is Denise Sherk's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Denise Sherk is licensed in California.

Dmand AI lists acute gastroduodenitis, chronic sinusitis, hemorrhoids, itchy rashes, migraine and chronic headache, swimmer's ear, tinnitus and upper respiratory infection (URI) among the conditions Denise Sherk treats.

CMS data shows 210 Medicare services from Denise Sherk across 4 procedure codes in 2024, for 122 Medicare patients. Medicare paid $15,893 for them. Every service was in an office.

CMS counts 122 Medicare patients who saw Denise Sherk in 2024. The largest group is 65 to 74, with 60 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 1.25, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Denise Sherk's median patient age at 56, with 68% women.

In 2024, Denise Sherk wrote 431 Medicare Part D claims for 161 patients. 89% of them were for generic drugs. CMS names the drug for 329 of them, across 9 drugs with 11 or more claims each, at $41,837 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Denise Sherk for performance year 2024, reported as part of a group. Denise Sherk accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Denise Sherk as offering telehealth.

CMS Open Payments shows 164 general payments to Denise Sherk from 21 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 98% of the total. Bausch Health Americas, Inc. paid the most, $859.